Abstract

Plants offer the unique opportunity to be engineered as bio-factories for the production of different antigens, enzymes and vaccines. Recently chloroplast transformation has gained strong interest in the field of Plant Made Vaccines (PMVs). An efficient cross-protective antigen against Mycobacterium is a 35 kDa protein encoded by mmpI gene in Mycobacterium leprae. Although vaccines against Mycobacterium infections are commercially available, they are neither affordable nor available for patients in resource poor countries. Thus, alternative cost-effective vaccine production approaches need to be developed. In the current study we have reported the possibility to generate transplastomic tobacco carrying 35-kDa protein conferring cross-protective resistance against two different pathogens Mycobacterium leprae and Mycobacterium avium. The mmpI gene along with an adjuvant Lymphotoxin-beta (LTB) was successfully transformed into tobacco chloroplast by the Polyethylene glycol (PEG) mediated transformation method. The PEG transformation method provides an effective and cost efficient transformation procedure and can easily be adopted in resource-poor countries in comparison to biolistic transformation. Integration of LTB and mmpI genes into transplastomic plant genome was confirmed by PCR analysis. In total four transplastomic lines were generated which were healthy and normal. All plants had regular growth pattern, they were able to reach maturity and produce viable seeds. Taken together, the data presented in the study is a valuable step forward to pave the way in the development of cost effective and easily administrable PMVs for resource-poor countries.

Highlights

  • For many centuries leprosy has been affecting humans as an individual and as a society

  • The mmpI gene encoded for a 35 kDa protein having immunogenic properties against Mycobacterium avium as well as Mycobacterium leprae

  • While the Escherichia coli heat-labile enterotoxin subunit B (LTB), used as a subunit protein to enhance the immunogenic response of the antigen, was controlled by 16S PlastidEncoded Polymerase (PEP) Promoter, Prrrn-62 Nuclear Encoded Polymerase (NEP) and G10L-UTR

Read more

Summary

Introduction

For many centuries leprosy has been affecting humans as an individual and as a society. First licensed vaccine against Mycobacterium leprae and Mycobacterium tuberculosis was BCG (Bacille Calmette-Guérin), which was successfully administrated to a young boy in 1921 [3]. The vaccine is effective against disseminated and meningeal TB in infants and young children, the protective efficacy of BCG vaccination against Mycobacterium leprae has not proved very effective [4]. Due to the poor performance of Multidrug Therapy (MDT) and BCG vaccination, especially in the developing areas of Asia and Africa, it is necessary to explore new immune protective vaccines and the identification of protective antigens is important for the subunit vaccine approach [5]. Immunization with DNA encoding mycobacterial antigens has already been proven to stimulate successful protective cell mediated immune responses against Mycobacterium tuberculosis and M. avium infection [6] and is a new strategy for leprosy control

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call